Evaluating New Biomarkers to Predict Kidney Problems After High-Risk Cardiac Surgery in Adults

What this Trial Is About

Researchers are examining new biomarkers found in blood and urine samples taken before and shortly after cardiac surgery to help predict kidney problems after surgery in patients at high risk. The study focuses on identifying factors that warn of acute kidney injury AKI after cardiac surgery and compares these novel markers with traditional ones. This observational study aims to improve early detection, preventive care, and overall safety in cardiac surgery outcomes. The project will collect medical history, lab data, and test specific biomarkers such as TWEAKR, galectin-9, perilipin-2, and CCN family member 1 from patients undergoing elective open chest cardiac surgery. Patients are categorized based on their risk factors and whether cardiopulmonary bypass CPB is used during surgery. A standard care bundle based on Kidney Disease Improving Global Outcome guidelines will be used to manage any AKI cases identified. Participants will be monitored for AKI occurrence within 7 days after surgery, which is the main outcome measured. Additional outcomes include AKI severity at various time points, major kidney events, need for kidney replacement therapy, mortality, ICU and hospital stay length, use of vasoactive drugs, and AKI in chronic kidney disease. The study involves collecting data and samples during the perioperative period to analyze these outcomes, with follow-up extending up to 30 days for mortality assessment.

Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients